Home  |  Contact

Cellosaurus MNNG/HOS Cl #5 (CVCL_0439)

[Text version]

Cell line name MNNG/HOS Cl #5
Synonyms MNNG/HOS; MNNG-HOS; HOS-MNNG; HOS/MNNG; MNNGHOS; MNNG-HOS (Cl#5); MNNG/HOS Clone F-5; MNNG; R-1059-D; TE85; Te85; TE-85; HOS-TE85; Hos TE-85; HOS TE 85; HOS TE85; HOS (TE85); HOS(TE85); HOS (TE85, Clone F5); MNNG-HOS (TE 85, clone F-5); HOS-Te85; TE 85.T; TE 85 ClF-5; TE-85 clone 5
Accession CVCL_0439
Secondary accession CVCL_3952
Resource Identification Initiative To cite this cell line use: MNNG/HOS Cl #5 (RRID:CVCL_0439)
Comments Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
Omics: Deep RNAseq analysis.
Omics: H3K4me1 ChIP-seq epigenome analysis.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Transcriptome analysis.
Misspelling: MNNG/HOSC1#5; In CCRID 3153C0001000000256.
Sequence variations Homozygous for CDKN2A deletion (PubMed=19787792).
TP53 p.Arg156Pro (c.467G>C) (ClinVar=VCV000634768) (PubMed=19787792).
Disease Osteosarcoma (NCIt: C9145)
Osteosarcoma (ORDO: Orphanet_668)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0312 (HOS)
Children:
CVCL_2402 (C1I)CVCL_2441 (E111)CVCL_4347 (II b)
CVCL_2546 (KHOS/NP)CVCL_AU05 (KRIB)CVCL_9U38 (MNNG/HOS/DXR1000)
CVCL_YE14 (TE-85-SF)
Sex of cell Female
Age at sampling 13Y
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; CLS; ECACC; KCLB; PubMed=19787792

Markers:
AmelogeninX
CSF1PO12
D2S133824,25
D3S135815
D5S81813
D7S82011,12
D8S117914 (CLS)
11,14 (PubMed=19787792)
D13S31712
D16S53910,13
D18S5114
D19S43313
D21S1131.2
FGA24
Penta D9,10
Penta E7,12
SE3320,21
TH016
TPOX8,11 (ATCC; CCRID; CLS; ECACC; KCLB)
11 (PubMed=19787792)
vWA18

Run an STR similarity search on this cell line
Web pages http://www.rccc.cytspb.rssi.ru/ecellbank/human/hMNNG-HOS%28TE85,clonF-5%29.htm
http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=1680
http://www.cellresource.cn/fdetail.aspx?id=3041
Publications

PubMed=265298; DOI=10.1002/ijc.2910190411
Rhim J.S., Putman D.L., Arnstein P., Huebner R.J., McAllister R.M.
Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine.
Int. J. Cancer 19:505-510(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6254071; DOI=10.1073/pnas.77.9.5258
Todaro G.J., Fryling C., De Larco J.E.
Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.
Proc. Natl. Acad. Sci. U.S.A. 77:5258-5262(1980)

PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)

PubMed=6575958; DOI=10.1007/BF02619599
Tsang K.-Y., Fudenberg H.H., Sun D.C., Pai G.S., Bishop L.R., Sager S.
Cultivation of human osteosarcoma cell lines in serum-free hormone supplemented medium.
In Vitro 19:515-521(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2823272; DOI=10.1073/pnas.84.21.7716
Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0
Clover J., Gowen M.
Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?
Bone 15:585-591(1994)

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4
Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Bocker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Cancer Genet. Cytogenet. 140:145-152(2003)

PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)

PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)

PubMed=24136885; DOI=10.1002/pbc.24801
Guma S.R., Lee D.A., Yu L., Gordon N., Hughes D., Stewart J., Wang W.L., Kleinerman E.S.
Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.
Pediatr. Blood Cancer 61:618-626(2014)

PubMed=26320182; DOI=10.18632/oncotarget.5177
Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H., Meltzer P.S., Khanna C.
Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.
Oncotarget 6:29469-29481(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29334376; DOI=10.1038/nm.4475
Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.
Nat. Med. 24:176-185(2018)

Cross-references
Cell line collections ATCC; CRL-1547
ATCC; CRL-7734 - Discontinued
ATCC; CRL-7735 - Discontinued
CLS; 300289/p447_MNNG-HOS
CLS; 300449/p503_HOS_(TE85)
ECACC; 87070201
KCLB; 21543
Cell line databases/resources CLDB; cl1703
CLDB; cl1704
CLDB; cl1705
CLDB; cl3510
CCRID; 3131C0001000700167
CCRID; 3153C0001000000256
Ontologies BTO; BTO:0005416
CLO; CLO_0003796
CLO; CLO_0007813
CLO; CLO_0007814
EFO; EFO_0002866
MCCL; MCC:0000334
Chemistry resources ChEMBL-Cells; CHEMBL3307282
ChEMBL-Targets; CHEMBL614038
ChEMBL-Targets; CHEMBL614173
Gene expression databases GEO; GSM879219
GEO; GSM1915008
GEO; GSM1915009
GEO; GSM1915010
GEO; GSM1915011
GEO; GSM1915025
GEO; GSM1915026
GEO; GSM1915027
GEO; GSM1915028
GEO; GSM1915029
GEO; GSM2635307
GEO; GSM2635308
Other Wikidata; Q54906271
Polymorphism and mutation databases Cosmic; 1044084
Cosmic; 1074402
Cosmic; 1529901
Cosmic; 2301584
IARC_TP53; 25022
Entry history
Entry creation04-Apr-2012
Last entry updated02-Jul-2020
Version number24